A new prostate cancer prognostic test is in the works and soon-to-be available worldwide.  MDxHealth recently signed an agreement that gives it licensing rights to market and manufacture the test.  The test, InformMDx, looks at the recently validated biomarker PDE4D7, and will help patients evaluate their risk of disease worsening and development of secondary tumors.

InformMDx is anticipated to provide valuable information to help guide post-biopsy treatment decisions at the time of diagnosis, as well as post-surgical treatment decisions following a prostatectomy.

You can read the entire article here: MDxHealth Announces Global Rights to Market Philips’ Prostate Cancer Prognostic Test.